Key result
Among obese patients receiving enoxaparin, only 36.5% achieved therapeutic anti-factor Xa levels, with no significant association between the dosing regimen used and therapeutic achievement (p>0.05).
Why the study?
Does the choice of enoxaparin dosing regimen affect the achievement of therapeutic anti-factor Xa levels in obese adult patients?
Population
52 obese adult patients receiving enoxaparin for treatment or prophylaxis indications in a hospital setting…
Design
Cohort
Follow-up
through their hospital course
Authors
Loading...
Caution advised for enoxaparin dosing in obesity given frequent subtherapeutic levels; leaves open optimal regimen validation in prospective trials.
Observational (n=52)
No
Does the choice of enoxaparin dosing regimen affect the achievement of therapeutic anti-factor Xa levels in obese adult patients?
p-value: p=>0.05
Standard and capped enoxaparin dosing regimens frequently result in nontherapeutic anti-Xa levels in obese patients, suggesting a need for individualized dosing guided by anti-Xa monitoring.
Tahaineh et al. (2018) conducted an observational in Obesity requiring enoxaparin (n=52). Enoxaparin was evaluated on Therapeutic anti-factor Xa levels (p=>0.05). Among obese patients receiving enoxaparin, only 36.5% achieved therapeutic anti-factor Xa levels, with no significant association between the dosing regimen used and therapeutic achievement (p>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: